Introduction
============

Socheongryong-Tang (SCRT), also known as Xiao-Qing-Long-Tang or Sho-Seiryu-To, has been commonly used for the treatment of inflammatory diseases, including allergic rhinitis and bronchial asthma, for several centuries in Asian countries ([@b1-ijmm-41-05-2771]-[@b3-ijmm-41-05-2771]). SCRT is composed of 8 herbal components and is classically administered depending on the specific diseases and symptoms of the patients ([@b4-ijmm-41-05-2771]). The major active ingredients of SCRT include liquiritigenin, isoliquiritigenin, glycyrrhizin and homogentisic acid, as well as paeoniflorin, kaempferol, gomisin B and C, *O*-methoxycinnamaldehyde, higenamine, L-ephedrine and 6-gingerol ([@b2-ijmm-41-05-2771]-[@b4-ijmm-41-05-2771]).

The inflammatory response is regulated by inflammatory mediators; among these, nitric oxide (NO), prostaglandin E~2~ (PGE~2~) and cytokines, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6, are considered to have central roles ([@b5-ijmm-41-05-2771],[@b6-ijmm-41-05-2771]). A significant feature of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2), which have a major role in the production of NO and PGE~2~, is that they are inducible enzymes. NO is a radical produced from L-arginine through the iNOS, which produces high amounts of NO during inflammation ([@b7-ijmm-41-05-2771]-[@b9-ijmm-41-05-2771]). Another enzyme involved in the generation of PGs, including PGH~2~ and PGE~2~, is COX. Specifically, COX-2 is responsible for mediating inflammation by producing PGE~2~ induced by factors including lipopolysaccharide (LPS) ([@b10-ijmm-41-05-2771],[@b11-ijmm-41-05-2771]). IL-1β, which is immunologically associated with TNF-α and IL-6, activates natural killer cells, B cells and T cells and induces fever by acting on the hypothalamus. IL-6 also has a central role in the acute immune response and increases antibody production by activating lymphocytes. It has also been reported that the levels of this cytokine are always increased in inflammatory lesions ([@b12-ijmm-41-05-2771],[@b13-ijmm-41-05-2771]). Furthermore, TNF-α is well known to have key roles in numerous autoimmune diseases and as a primary mediator in inflammatory reactions that occur during immune responses via stimulation of the secretion of other inflammatory cytokines ([@b12-ijmm-41-05-2771],[@b14-ijmm-41-05-2771]).

Nuclear factor κB (NF-κB) is a transcription factor associated with the transactivation of diverse genes involved in the regulation of tumorigenesis, cellular proliferation and the inflammatory response ([@b15-ijmm-41-05-2771]). In addition, mitogen-activated protein kinases (MAPKs) are kinases that are specific to serine and threonine. They include p38 MAPK (p38), extracellular signal-regulated kinases (ERKs) and c-Jun NH~2~-terminal kinases (JNKs), which have key roles in the modulation of the inflammatory response ([@b16-ijmm-41-05-2771]). The signaling pathways of MAPKs may activate NF-κB and cause the expression of pro-inflammatory genes ([@b12-ijmm-41-05-2771]-[@b14-ijmm-41-05-2771]).

Several studies have reported on the anti-allergic activity of SCRT in guinea pig and mouse models of airway inflammation ([@b1-ijmm-41-05-2771],[@b17-ijmm-41-05-2771],[@b18-ijmm-41-05-2771]). In addition, SCRT was demonstrated to exhibit an immunomodulaory effect in allergen-sensitized mice ([@b19-ijmm-41-05-2771]). However, to the best of our knowledge, the underlying molecular mechanisms of the anti-inflammatory effects of SCRT have remained elusive. Therefore, the present study evaluated the effects of SCRT on the NF-κB and MAPKs signaling pathways and on NF-κB-dependent induction of inflammatory cytokines, iNOS and COX-2 in RAW 264.7 cells induced with LPS. Furthermore, the effects of SCRT on carrageenan (CA)-induced acute edematous inflammation were examined by histomorphometry and histopathology *in vivo*. The present study provided a molecular basis for the inhibitory effects of SCRT on inflammatory responses and expanded the current knowledge on the mechanism of action to provide a scientific rationale for the use of SCRT as complementary and alternative medicine.

Materials and methods
=====================

Chemicals and reagents
----------------------

Five reference standards, namely ephedrine, paeoniflorin, cinnamic acid, glycyrrhizin and gomisin-A, were obtained from Wako Inc. (Wako, Japan). The purity of the 5 standards was \>98%. Acetonitrile, methanol and other solvents for ultra performance liquid chromatograpy (UPLC) analysis were from J.T. Baker (Avantor, Center Valley, PA, USA). Anti-NF-κB (cat. no. sc-8008), anti-lamin A/C (cat. no. sc-376248), anti-phosphorylated (p) inhibitor of NF-κB (p-I-κBa; cat. no. sc-8404) and anti-COX-2 (cat. no. sc-19999) antibodies were purchased from Santa Cruz Biotechnology Inc. (Dallas, TX, USA) and JNK (cat. no. 9252), p-JNK (cat. no. 9255), ERK1/2 (cat. no. 9102), p-ERK1/2 (cat. no. 9101), p38 (cat. no. 9212) and p-p38 (cat. no. 9211) antibodies were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Anti-β-actin (cat. no. sc-58673) and peroxidase-conjugated secondary (cat. no. sc-51625) antibodies were acquired from Santa Cruz Biotechnology Inc. Anti-iNOS antibody (cat. no. MABN527) was acquired from Calbiochem (San Diego, CA, USA). The immunoassay kit (cat. no. KGE004B) for PGE~2~ was obtained from R&D Systems (Minneapolis, MN, USA) and ELISA kits for IL-1β (cat. no. EMIL1B), IL-6 (cat. no. EM2IL6) and TNF-α (cat. no. EMTNFA) were purchased from Pierce (Thermo Fisher Scientific, Inc., Waltham, MA, USA). A peroxidase substrate kit (cat. no. SK-4100) and vectastain elite ABC kit (cat. no. PK-6200) were acquired from Vector Lab. Inc. (Burlingame, CA, USA). LPS, sulfanilamide, sodium nitrite, MTT, dexamethasone (DEXA), CA and other chemicals were obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany).

Preparation of SCRT
-------------------

SCRT (2X, 80 g) consisted of the following medicinal herbs: 12 g of Ephedrae Herba (*Ephedra sinica* Stadf.), 12 g of Paeoniae Radix (*Paeonia lactiflora* Pall.), 12 g of Turcz. Ball. Schizandrae Fructus (*Schizandra chinensis*), 12 g of Tenore et Breit. Pinelliae Rhizoma (*Pinellia ternata*), 8 g of Asiasari Radix (*Asarum sieboldii* F. Maekawa), 8 g of Zingiberis Rhizoma (*Zingiber officinale* Rosc.), 8 g of Cinnamomi Ramulus (*Cinnamomum cassia* Blume.) and 8 g of Glycyrrhizae Radix (*Glycyrrhiza glabra* L.). All medicinal herbs were purchased from Daewon Pharmacy (Daegu, Korea) and voucher specimens (no. PNU10-28) were deposited in the Herbarium at the School of Korean Medicine, Pusan National University (Busan, Korea). The mixture (80 g) was extracted with 1.2 l of boiling distilled water for at least 3 h, then filtered through filter paper (Hyundai Micro no. 20; Hyundai Pharmaceutical Co., Ltd., Seoul, South Korea) and the filtrate was then lyophilized. The percentage yield of lyophilized SCRT extract was 14.8%. The lyophilized powder of SCRT was dissolved in distilled water immediately prior to use, and then filter-sterilized (Nalgene, Rochester, NY, USA) using a 0.2-*μ*m syringe filter to avoid contamination.

Chemical profiling of SCRT by UPLC
----------------------------------

The UPLC operating system was equipped with a Waters ACQUITY™ (Waters Corp., Milford, MA, USA) pump and photodiode array detector. Signal of the detector was indicated using the Empower Data System. The separation was performed using a Waters ACQUITY™ BEH C~18~ column (2.1×100 cm; 1.7 *μ*m particle size; Waters Corp.). The mobile phase was comprised of 0.1% formic acid in water and 0.1% formic acid in aceto-nitrile with application of gradient elution (0.4 ml/min). The volume for injection was always 2 *μ*l, the ultraviolet wavelength for detection was 254 nm and the column temperature was kept at 25°C. To obtain the chemical profile of SCRT, the lyophilized powder of SCRT aqueous extracts was dissolved in methanol (10 mg/ml). Prior to UPLC analysis, the sample solution was filtered using a 0.22-*μ*m filter. In addition, standard solutions of 5 components, ephedrine, paeoniflorin, cinnamic acid, glycyrrhizin and gomisin-A, were prepared (1,000 *μ*g/ml in methanol). All solutions were stored at 4°C.

Cell culture
------------

RAW 264.7 cells (American Type Culture Collection, Manassas, VA, USA) were cultured in Dulbecco\'s modified Eagle\'s medium (HyClone; Thermo Fisher Scientific, Inc.) containing 10% heat-inactivated fetal bovine serum (Sigma-Aldrich; Merck KGaA), 100 *μ*g/ml streptomycin and 100 U/ml penicillin (Gibco; Thermo Fisher Scientific, Inc.) at 37°C in a 5% CO~2~ incubator.

MTT assay
---------

To examine the cytotoxicity of SCRT, RAW 264.7 cells (5×10^4^/well) were seeded in a 96-well plate. The cells were serum-starved for 16-17 h, after which they were pre-treated with diverse concentrations of SCRT for 1 h, followed by induction with LPS (1 *μ*g/ml) at 37°C with 5% CO~2~ for an additional 20 h. After incubation, the cells were stained with MTT (4 h, 0.5 mg/ml). The media were then removed and formazan crystals were dissolved by adding dimethyl sulfoxide at 200 *μ*l/well. Next, the absorbance was read at 570 nm with an automated microplate reader (Infinite 200 Pro; Tecan, Männedorf, Switzerland). The viability of cells relative to that of the untreated cells was calculated as follows: Viability (% of control) = (optical density of treated sample)/(optical density of untreated control) × 100%.

Measurement of NO
-----------------

According to previously established procedures ([@b20-ijmm-41-05-2771]-[@b23-ijmm-41-05-2771]), RAW 264.7 cells (5×10^5^ cells/ml) were cultured for \~16 h and then treated with diverse concentrations of SCRT for 1 h, followed by induction with LPS (1 *μ*g/ml). Cells were then incubated in a 5% CO~2~ incubator (37°C) for 20 h, after which the culture supernatants were collected. NO was measured by reaction with 100 *μ*l Griess reagent \[0.1% N-(1-naphthy)-ethylenediamine dihydrochloride + 1% sulfa-nilamide in the 5% phosphoric acid; Hoffmann-La Roche AG, Basel, Switzerland\] with 100 *μ*l supernatant of cells at 25°C for 15 min. The absorbance was read at 540 nm with a microplate reader (Tecan). The standard curve was drawn using NaNO~2~.

IL-1*β*, IL-6, TNF-α and PGE~2~ assays
--------------------------------------

RAW 264.7 cells at a concentration of 5×10^5^ cells/ml were cultured for 16 h, after which they were pre-treated with diverse concentrations of SCRT for 1 h, and then stimulated with 1 *μ*g/ml LPS. The culture supernatants were collected at 20 h after LPS stimulation and levels of IL-1β, IL-6, TNF-α and PGE~2~ were quantified using a microplate reader (Tecan).

Preparation of whole-cell lysates and nuclear extracts
------------------------------------------------------

To prepare whole-cell lysates, control and SCRT-treated RAW 264.7 cells were harvested by centrifugation and rinsed with PBS. Washed pellets of cells were resuspended in lysis buffer \[250 mM NaCl, 50 mM 4-(2-hydroxyethyl)-1-piper-azineethanesulfonic acid (HEPES; pH 7.0), 0.1% Nonidet P (NP)-40, 5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol (DTT), 0.5 mM sodium orthovanadate and 5 mM NaF\] containing 5 *μ*g/ml each of aprotinin and leupeptin, and then incubated at 4°C for 20 min. Microcentrifugation was performed to remove cell debris, accomplished by rapid freezing of supernatants. To prepare nuclear extracts, cells were then swollen by adding lysis buffer \[10 mM KCl, protease inhibitor cocktail, 1 mM DTT, 10 mM HEPES (pH 7.9), 1.5 mM MgCl~2~ and 0.2% NP-40 (Roche Diagnostics, Indianapolis, IN, USA)\]. The samples were then incubated on ice for 10 min and centrifuged at 4°C for 5 min. Pellets containing the nuclei were suspended in 50 *μ*l buffer containing 1.5 mM MgCl~2~, 20 mM HEPES (pH 7.9), protease inhibitor cocktail, 420 mM NaCl, 1 mM DTT and 20% glycerol, followed by incubation on a shaker at 4°C for 30 min. Finally, samples were centrifuged (16,000 × g) for 10 min. A Bradford assay (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was applied for the determination of protein concentrations.

Western blot analysis
---------------------

Protein from untreated or treated cell extracts (30 *μ*g) was subjected to 8% SDS-PAGE, after which they were electroblotted onto nitrocellulose membranes (Thermo Fisher Scientific, Inc.). Samples were then blocked in 5% skim milk in 0.1% Tween-20/Tris-buffered saline (TTBS) at room temperature for 1 h, incubated overnight in the primary antibody solutions (1:1,000 dilution) at 4°C. The blots were subsequently rinsed with TTBS, stirred with a dilute solution of horseradish peroxidase-conjugated antibody (1:1,000) at 25°C for 1 h, and then washed 3 times with TTBS. Western blot detection reagents (enhanced chemiluminescence; GE Healthcare, Little Chalfont, UK) were utilized to develop the blots.

CA-induced paw edema
--------------------

Paw edema experiments were performed according to previously established procedures ([@b20-ijmm-41-05-2771]-[@b23-ijmm-41-05-2771]). All animal procedures were performed in accordance with the national regulations regarding the welfare and usage of laboratory animals and protocols were approved by the Institutional Animal Care and Use Committee of Daegu Haany University (Gyeongsan, South Korea; approval no. DHU2011-020). Male Sprague Dawley rats (age, 4 weeks; weight, 80-100 g) were obtained from Samtako Co. (Osan, South Korea) and acclimatized for one week. The animals were reared in a pathogen-free environment at 20-23°C under a 12-h light/dark cycle and a relative humidity of 50% with commercial chow (Nestle Purina PetCare Ltd., Seoul, South Korea) and water provided *ad libitum*. Rats (n=25) were randomly divided into 5 groups that consisted of 5 animals each. SCRT was administered to rats by oral gavage at different doses (0.3 and 1.0 g/kg/day) for 3 consecutive days. An anti-inflammatory drug, DEXA, was applied as a positive control. To cause acute-phase inflammation, rats received a subcutaneous injection of a CA solution (1% in saline; 0.1 ml/rat) into the right hind paw at 1 h after SCRT or vehicle treatment. The paw volumes were measured for 4 h after injection with 1-h intervals. The paw volume was recorded using a plethysmometer (Ugo Basile, Varese, Italy).

Histological examination
------------------------

The paw skins (ventrum and dorsum) were separated and fixed in neutral buffered formalin (10%), subsequently embedded in paraffin, sliced (3-4 *μ*m) and stained using hematoxylin and eosin for histopathological profiles and toluidine blue for mast cells. To observe the changes induced by CA treatment in greater detail, the thicknesses of dorsal and ventral skins (from the epidermis to the dermis, excluding keratin layers; *μ*m/paw) were measured using an automated image analyzer (DMI-300; DMI, Daegu, South Korea) and a light microscope (Nikon, Tokyo, Japan) under 40× magnification, and the mast and infiltrated inflammatory cells were counted by an automated image analyzer and denoted as cells/mm^2^ of dermis under 200× magnification.

Statistical analysis
--------------------

All values are expressed as the mean ± standard deviation. Multiple-comparisons tests were performed for different dose groups. Levene\'s test was used to test for homogeneity in variance. If the Levene test indicated an insignificant deviation from variance homogeneity, the results were analyzed by one way analysis of variance, followed by the least-significant differences multi-comparison test assess significant differences between pairs of groups. For non-parametric analysis, the Kruskal-Wallis H test was used. When a significant difference was indicated by a Kruskal-Wallis H test, the Mann-Whitney U test was performed to identify specific pairs that differed significantly. SPSS (version 14.0K; SPSS, Inc., Chicago, IL, USA) was applied for statistical analyses. Differences were considered significant at P\<0.05.

Results
=======

Analysis of SCRT
----------------

Determination of 5 markers, ephedrine, paeoniflorin, cinnamic acid, glycyrrhizin, and gomisin-A, in SCRT was established using an UPLC system. The contents of the 5 components in SCRT were calculated from the standard curve ([Table I](#tI-ijmm-41-05-2771){ref-type="table"} and [Fig. 1](#f1-ijmm-41-05-2771){ref-type="fig"}).

SCRT inhibits LPS-stimulated NO and PGE~2~ production and reduction in cell viability
-------------------------------------------------------------------------------------

To measure the inhibitory effects of SCRT on LPS-stimulated NO production in RAW 264.7 cells, 0.25, 0.5 and 1 mg/ml SCRT were analyzed. Compared with the control, treatment with LPS (1 *μ*g/ml for 20 h) significantly increased NO production. However, treatment with SCRT significantly inhibited LPS-stimulated NO production ([Fig. 2A](#f2-ijmm-41-05-2771){ref-type="fig"}, left). SCRT (0.25-1 mg/ml) in the absence of LPS did not change the basal levels of NO production in RAW 264.7 cells ([Fig. 2A](#f2-ijmm-41-05-2771){ref-type="fig"}, right). In addition, the effects of SCRT on LPS-stimulated PGE~2~ production were also measured. When compared with the control, LPS treatment significantly increased PGE~2~ production. However, treatment with SCRT significantly suppressed LPS-stimulated PGE~2~ production ([Fig. 2B](#f2-ijmm-41-05-2771){ref-type="fig"}). Furthermore, the possible cytotoxic effects of SCRT in RAW 264.7 cells were examined using an MTT assay. The viability of cells was not affected by SCRT treatment, at least up to the SCRT concentration of 1 mg/ml ([Fig. 2C](#f2-ijmm-41-05-2771){ref-type="fig"}).

SCRT inhibits LPS-stimulated iNOS and COX-2 expression
------------------------------------------------------

To examine whether the inhibitory effects of SCRT were associated with the expression of iNOS and COX-2, western blot analysis was performed. The protein levels of iNOS and COX-2 were highly upregulated in response to LPS, while treatment with SCRT significantly inhibited the upregulation of iNOS and COX-2 in a dose-dependent manner ([Fig. 3A and B](#f3-ijmm-41-05-2771){ref-type="fig"}).

SCRT reduces LPS-inducible IL-1β, IL-6 and TNF-α production
-----------------------------------------------------------

The present study investigated the effects of SCRT on LPS-inducible IL-1β, IL-6 and TNF-α production by ELISA. When compared with the control, treatment with LPS (1 *μ*g/ml for 20 h) significantly increased the production of IL-1β, IL-6 and TNF-α (P\<0.01). However, treatment with SCRT significantly inhibited LPS-inducible IL-1β, IL-6 and TNF-α production in a dose-dependent manner ([Fig. 4](#f4-ijmm-41-05-2771){ref-type="fig"}).

SCRT inhibits LPS-stimulated activation of NF-κB
------------------------------------------------

To examine whether the reduction of nuclear translocation of NF-κB (p65) by SCRT was due to the inhibition of p-I-κBα, western blot analysis was performed to evaluate levels of p-I-κBα and nuclear NF-κB (p65). Treatment with LPS for 15 min increased the levels of p-I-κBα and SCRT significantly blocked this LPS-stimulated increase ([Fig. 5A](#f5-ijmm-41-05-2771){ref-type="fig"}). In addition, NF-κB (p65) was accumulated in the nucleus after treatment with LPS for 15 min, which was significantly inhibited by pretreatment with SCRT ([Fig. 5B](#f5-ijmm-41-05-2771){ref-type="fig"}).

Inhibitory effects of SCRT on LPS-stimulated phosphorylation of MAPKs
---------------------------------------------------------------------

To examine the molecular targets of SCRT and associated signaling pathways, the effects of SCRT on LPS-stimulated phosphorylation of JNK, ERK1/2 and p38 in RAW 264.7 cells were evaluated. As presented in [Fig. 6](#f6-ijmm-41-05-2771){ref-type="fig"}, the phosphorylation of JNK, ERK1/2 and p38 was significantly increased after LPS treatment (1 *μ*g/ml) for 15 min. However, treatment with SCRT (1 mg/ml) significantly decreased the phosphorylation of JNK and ERK1/2, whereas the phosphorylation of p38 was unaffected.

SCRT reduces CA-induced paw edema, as well as iNOS and COX-2 protein expression in paw tissues
----------------------------------------------------------------------------------------------

In accordance with the results of previous studies ([@b20-ijmm-41-05-2771]-[@b23-ijmm-41-05-2771]), the present results indicated that CA injection significantly increased the paw swelling relative to the control group within 4 h. However, treatment with DEXA (positive control; 1 mg/kg/day, *per os*) resulted in a significant decrease in edema formation relative to that in the CA group (P\<0.01). Treatment with SCRT (0.3 and 1 g/kg/day, per os, 3 days) also significantly decreased paw edema volumes within 4 h ([Fig. 7A](#f7-ijmm-41-05-2771){ref-type="fig"}). CA significantly increased the expression of iNOS and COX-2 protein relative to the control in the paw tissues. However, DEXA significantly decreased the expression of iNOS and COX-2 protein. In addition, SCRT (1 g/kg) also significantly decreased the expression of iNOS and COX-2 protein (P\<0.001; [Fig. 7B](#f7-ijmm-41-05-2771){ref-type="fig"}).

Histological examination
------------------------

Representative histological profiles of the dorsal and ventral pedis skins observed after CA and DEXA or SCRT treatment are presented in [Figs. 8](#f8-ijmm-41-05-2771){ref-type="fig"} and [9](#f9-ijmm-41-05-2771){ref-type="fig"}, respectively. In addition, the histomorphometrical measurements of the dorsal and ventral pedis skins are listed in [Table II](#tII-ijmm-41-05-2771){ref-type="table"}. The thicknesses of the dorsal and ventral pedis skins at 4 h after CA injection were increased by 152.50 and 132.14%, respectively, as compared with those in the control group. In addition, the thickness of the dorsal pedis skin in rats treated with DEXA and SCRT at 0.3 g/kg (low dose) and 1 g/kg (high dose) was decreased by 44.80, 18.67 and 31.05%, respectively, and that of the ventral pedis skin was decreased by 33.97, 5.27 and 19.73%, respectively, compared with that in the CA group. Furthermore, the number of infiltrated inflammatory cells in the dorsal and ventral pedis skins at 4 h after CA injection was increased by 909.09 and 2,244.55% relative to that in the control group, respectively. The number of infiltrated inflammatory cells in the dorsal pedis skin of rats treated with DEXA and SCRT at 0.3 g/kg (low dose) and 1 g/kg (high dose) was decreased by 60.78, 10.33 and 39.92%, and that in the ventral pedis skin was decreased by 58.32, 12.84 and 29.31% compared with that in the CA group, respectively. Finally, the number of mast cells in the dorsal and ventral pedis skin in the CA group was decreased by 66.67 and 65.71% relative to that in the control group, respectively. In addition, the number of mast cells in the dorsal pedis skins of rats treated with DEXA and SCRT at 0.3 g/kg (low dose) and 1 g/kg (high dose) was changed by 106.19, 15.46 and 110.31%, and that in the ventral pedis skin was changed by 131.67, −8.33 and 71.67% compared with that in the CA group, respectively ([Table II](#tII-ijmm-41-05-2771){ref-type="table"}).

Discussion
==========

Although the exact molecular mechanisms associated with herbal medicines have remained to be fully elucidated, herbal medications have been widely used for centuries and have become attractive therapeutics due to fewer side-effects than certain pharmaceutical drugs. In traditional Korean medicine, SCRT has been commonly used to treat a variety of inflammatory allergic diseases, including allergic rhinitis and bronchial asthma ([@b1-ijmm-41-05-2771]-[@b3-ijmm-41-05-2771]). However, only few studies have provided a scientific assessment of the benefits of SCRT. Accordingly, the present study investigated the influences of SCRT on inflammatory responses of RAW 264.7 cells and rats.

Inflammation has a key role in health as well as in disease. Specifically, it is a response of the body to injury linked to harmful chemical or physical stimuli and microbiological toxins that is involved in multiple pathologies, including arthritis, asthma, inflammatory bowel diseases and atherosclerosis. The inflammatory response is intended to demolish or inactivate invading organisms and set the stage for tissue repair ([@b6-ijmm-41-05-2771]). NO produced by NOS is associated with the development of inflammation after CA administration, and NO generated by iNOS is associated with the maintenance of the inflammatory responses ([@b24-ijmm-41-05-2771]). Increases of iNOS activity that influences inflammatory agents, including endotoxin, interferon-γ, IL-1β and TNF-α, may cause shock and inflammatory responses in humans ([@b25-ijmm-41-05-2771],[@b26-ijmm-41-05-2771]). Furthermore, it has been reported that COX-2 is activated during the inflammatory response to produce PGE~2~, which contributes to the formation of tumors by inhibiting apoptosis and inducing cell division, cancer metastasis and angiogenesis ([@b27-ijmm-41-05-2771]). In the present study, SCRT significantly inhibited the LPS-stimulated NO production and expression of iNOS protein in RAW 264.7 cells. Furthermore, the PGE~2~ assay and immunoblot analysis revealed that SCRT significantly blocked the induction of PGE~2~ and COX-2 protein by LPS. In paw tissues, treatment with CA resulted in significantly increased expression of iNOS and COX-2 protein in comparison with the control group. However, DEXA significantly decreased the expression of iNOS and COX-2 protein. SCRT (1 g/kg) also significantly inhibited the expression of iNOS and COX-2 protein. These results may indirectly suggest that the therapeutic effects of SCRT on various inflammatory symptoms of allergic rhinitis and bronchial asthma are partly due to inhibition of NO and PGE~2~ production as well as expression of iNOS and COX-2 protein. TNF-α, IL-1β and IL-6 are frequently encountered pro-inflammatory cytokines that are involved in the interaction with various target cells as well as diverse immunological functions ([@b12-ijmm-41-05-2771]-[@b14-ijmm-41-05-2771]). These cytokines also mediate immunity and inflammation. Large amounts of TNF-α, IL-1β and IL-6 are released by LPS in macrophages. NF-κB is also known have a key role in transmitting proinflammatory cytokine signals to the nucleus ([@b13-ijmm-41-05-2771]). Treatment with SCRT significantly inhibited the production of these cytokines, suggesting that SCRT inhibits the expression of these specific genes associated with the inflammatory process. The present results demonstrated that SCRT is a strong inhibitor of the production of IL-1β, IL-6 and TNF-α. Furthermore, the inhibitory mechanism of SCRT on pro-inflammatory cytokines may indicate an important strategy to limit pathological inflammation.

NF-κB is a typical transcription factor that controls the expression of genes associated with apoptosis, immune responses and the cell cycle. Unsuitable NF-κB activation may mediate tumorigenesis and inflammation. However, suppression of NF-κB activity should be useful in the treatment and prevention of cancer ([@b28-ijmm-41-05-2771]). The present study demonstrated that SCRT significantly prevented LPS-stimulated NF-κB activation. It has been suggested that NF-κB is associated with the regulation of COX-2 and iNOS protein expression, and that several chemopreventive phytochemicals inhibited COX-2 and iNOS protein expression by suppressing NF-κB activation ([@b20-ijmm-41-05-2771],[@b29-ijmm-41-05-2771]). In addition, the NF-κB pathway is a major regulator of LPS-induced pro-inflammatory cytokine release ([@b30-ijmm-41-05-2771]). The present results revealed that LPS increased the levels of p-I-κBα and NF-κB (p65), whereas treatment with SCRT resulted in reduced p-I-κBα levels and inhibited the nuclear translocation of NF-κB. Taken together, these results indicate that suppression of NF-κB activation by SCRT was correlated with inhibition of induction of iNOS, COX-2 and pro-inflammatory cytokines by SCRT. Furthermore, MAPKs, a family of protein threonine/serine kinases, represent a major component of intracellular signaling ([@b31-ijmm-41-05-2771],[@b32-ijmm-41-05-2771]). LPS has been reported to induce macrophages, leading to increased activation and phosphorylation of JNK, ERK1/2 and p38 ([@b33-ijmm-41-05-2771]). In the present study, it was demonstrated that SCRT (1 mg/ml) significantly suppressed the phosphorylation of JNK and ERK1/2, whereas the phosphorylation of p38 was unaffected. Furthermore, the results of the present demonstrated an association between inhibited phosphorylation of JNK and ERK1/2 and inactivation of NF-κB. Therefore, the aforementioned data suggests that the anti-inflammatory activities of SCRT may be due to inhibition of LPS-stimulated activation of NF-kB and phosphorylation of JNK and ERK1/2 *in vitro*.

Local treatment with CA induces severe acute edematous inflammation, and a variety of inflammatory mediators produced from resident macrophages, damaged tissues, polymorphonuclear cells (e.g., neutrophils) and mast cells are involved in the associated pathogenesis ([@b34-ijmm-41-05-2771]-[@b37-ijmm-41-05-2771]). Histopathologically, infiltration of inflammatory cells and loosening of connective tissues were observed around CA-treated sites ([@b38-ijmm-41-05-2771]-[@b40-ijmm-41-05-2771]). Thus, the present study used CA-induced paw edema as a representative model to assess the anti-inflammatory activities of therapeutic candidates ([@b20-ijmm-41-05-2771]-[@b23-ijmm-41-05-2771],[@b37-ijmm-41-05-2771],[@b41-ijmm-41-05-2771],[@b42-ijmm-41-05-2771]), while the *in vivo* and *in vitro* models may exhibit differences of major cell types. In the present study, prominent increases of inflammatory infiltrated cells with increases in skin thicknesses on the dorsal and ventral pedis were observed following treatment of rat paw skins with CA. However, the CA-induced acute edematous inflammation was significantly inhibited by treatment with the higher dosage of SCRT and DEXA (P\<0.01). In rats treated with the lower dose of SCRT, a significant decrease in the dorsal pedis skin thickness relative to that in the CA group was demonstrated, but no significant changes in the ventral pedis skin thicknesses or number of infiltrated inflammatory cells on the dorsal and ventral pedis skin tissues were demonstrated. These results are considered as direct evidence that the higher dosage of SCRT has beneficial anti-inflammatory effects sufficient to reduce inflammatory edema and cell infiltration, but that the lower dosage was only effective against edematous changes restricted to dorsal pedis skin tissues but that it was not sufficient to reduce inflammatory cell infiltration and edema in ventral pedis skin tissues. Mast cells are distributed in the body and have an important role in a variety of inflammatory and allergic diseases. These cells also have cell surface immunoglobulin (Ig)E receptors and are provoked by interaction between bound IgE and the pertinent antigen ([@b43-ijmm-41-05-2771]). Following activation, mast cells release a variety of bioactive substances, including various lipid mediators and histamine that cause an immediate-type allergic reaction. Mast cell degranulation has been also known to increase in the acute ([@b44-ijmm-41-05-2771],[@b45-ijmm-41-05-2771]), as well as the chronic stage ([@b46-ijmm-41-05-2771]-[@b48-ijmm-41-05-2771]) of diverse inflammatory and allergic diseases. Noticeable increases of mast cell degranulation in dermis tissue have been observed in CA-induced acute inflammation, and the inhibition of these mast cell activities (degranulation) has been used as a beneficial index to predict the efficacy of anti-inflammatory drugs ([@b34-ijmm-41-05-2771],[@b49-ijmm-41-05-2771],[@b50-ijmm-41-05-2771]). In the present study, treatment with the higher dosage of SCRT and DEXA markedly and significantly inhibited mast cell degranulation and maintained the mast cell numbers in the dermis of the CA-induced rats (P\<0.01), but no significant changes in mast cell numbers were observed in rats treated with the lower dosage of SCRT compared with those in the CA group on the dorsal and ventral pedis skins. These results provide direct evidence that the higher dosage of SCRT exerted anti-inflammatory effects through the control of mast cell activation, as indicated by at least partial degranulation, but that the lower dosage of SCRT did not. Furthermore, as the results of the toluidine blue staining of edematous tissues indicated that SCRT inhibited the numbers of degranulated mast cells, SCRT may have therapeutic potential to reduce type I hypersensitivity. In the present *in vivo* study, rats were injected with CA once, without any previous injection of any sensitizing agent, so that hypersensitivity could not be assessed. As previously established, CA injection causes a maximum increase in paw volumes within 4 h, and in the present study, paw volumes were monitored at 1-h time intervals for 4 h. Thus, the effect of SCRT on type IV hypersensitivity reactions could also not be determined.

SCRT is an extract from a blend of 8 medicinal herbs. Several active components of SCRT have been reported to exert anti-inflammatory activities. Ephedrine and pseudoephedrine are stereoisomers isolated from the plant *Ephedra sinica* (Ephedraceae family) or the traditional Chinese medicinal herb Ma Huang ([@b51-ijmm-41-05-2771]). These compounds have also been reported to exert powerful anti-inflammatory effects against D-galactosamine/LPS-stimulated acute liver failure in rats ([@b52-ijmm-41-05-2771]). Furthermore, ephedrine and pseudoephed-rine were reported to suppress CA-induced hind paw edema in mice. Hind paw edema stimulated by prostaglandin E, histamine and bradykinin was reported to be inhibited by these compounds, demonstrating that they exert anti-inflammatory effects ([@b53-ijmm-41-05-2771]). Paeoniflorin has pharmacological properties, including anti-inflammatory and immunomodulatory effects, as well as the ability to suppress rheumatic diseases ([@b18-ijmm-41-05-2771]). In addition, Liu *et al* ([@b54-ijmm-41-05-2771]) reported that paeoniflorin reduced 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced toxicity by suppression of neuroinflammation via activation of adenosine A1 receptor, and that paeoniflorin may be a useful neuroprotective compound for the treatment of Parkinson\'s disease. Cinnamic acid was reported to have significant anti-inflammatory activities *in vitro* and *in vivo* ([@b55-ijmm-41-05-2771]). Furthermore, this compound acts as a lipoxygenase inhibitor with antioxidant, anti-inflammatory and anticancer activity ([@b56-ijmm-41-05-2771],[@b57-ijmm-41-05-2771]). Glycyrrhizin, a triterpene glycoside from the roots of licorice, resulted in widely inhibited induction of inflammatory mediators stimulated by CpG-DNA in RAW 264.7 cells, as well as attenuated inflammatory responses stimulated by toll-like receptor (TLR)3 and TLR4 ([@b58-ijmm-41-05-2771]). In addition, inhibition of NF-κB activity and IL-8 production in lung cells and attenuation of CA-induced lung damage in mice by glycyrrhizin have been demonstrated ([@b59-ijmm-41-05-2771],[@b60-ijmm-41-05-2771]). Gomisin A inhibits the activation of NF-κB and oxidative stress, leading to the suppression of pro-inflammatory mediators by attenuating CCl~4~-stimulated acute liver damage ([@b61-ijmm-41-05-2771]). Furthermore, gomisin A was reported to have neuroprotective effects by relieving the microglia-mediated neuroinflammatory response through inhibition of TLR4-mediated MAPKs and NF-κB signaling pathways ([@b62-ijmm-41-05-2771]). UPLC analysis revealed that the major active components of SCRT are ephedrine, paeoniflorin, cinnamic acid, glycyrrhizin and gomisin-A. Accordingly, it is suggested that the anti-inflammatory properties of SCRT on LPS-stimulated RAW 264.7 cells and CA-induced rat paw edema may be due to the action of these 5 compounds.

In conclusion, the present results clearly demonstrated that SCRT has anti-inflammatory activities through decreasing the production of inflammatory mediators, including PGE~2~, NO and pro-inflammatory cytokines via inhibition of the signaling pathways of JNK, ERK1/2 and NF-κB in the LPS-stimulated RAW 264.7 cells. In addition, the results from the CA-induced paw edema model demonstrated an anti-edema effect of SCRT. Furthermore, SCRT (1 g/kg) inhibited acute edematous inflammation through inhibition of mast cell degranulation and infiltration of inflammatory cells. Therefore, the present study provided scientific evidence for the anti-inflammatory activities of SCRT.
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![UPLC chromatogram of 5 marker compounds in SCRT. (A) UPLC chromatogram of commercial standard compounds. (B) UPLC chromatogram of 5 marker compounds in SCRT. The chromatograms were obtained at 254 nm. UPLC, ultra performance liquid chromatography; AU, absorbance units; SCRT, Socheongryong-Tang.](IJMM-41-05-2771-g00){#f1-ijmm-41-05-2771}

![Effects of SCRT on the production of (A) NO and (B) PGE~2~, and on (C) the viability of LPS-stimulated RAW 264.7 cells. Cells at 5×10^5^/ml were treated with different concentrations of SCRT (0.25, 0.5 or 1 mg/ml) for 1 h, followed by induction with 1 *μ*g/ml LPS for 20 h. Control groups were incubated with vehicle instead. The concentrations of NO and PGE~2~ in the culture supernatant were determined. In addition, the effects of SCRT on the viability of the cells were determined by an MTT assay. Values are expressed as the mean ± standard deviation of 3 replicates for each condition. ^\*\*^P\<0.01 vs. vehicle-treated control; ^\#\#^P\<0.01, ^\#\#\#^P\<0.001 vs. LPS only group. SCRT, Socheongryong-Tang; LPS, lipopolysaccharide; NO, nitric oxide; PGE~2~, prostaglandin E~2~.](IJMM-41-05-2771-g01){#f2-ijmm-41-05-2771}

![Inhibitory effects of SCRT on LPS-induced expression of (A) iNOS and (B) COX-2. RAW 264.7 cells (5×10^5^ cells/ml) were treated with different concentrations of SCRT (0.25, 0.5 and 1 mg/ml) for 1 h, followed by induction with 1 *μ*g/ml of LPS for 20 h. Control cells were incubated with vehicle alone. The protein levels of COX-2 and iNOS were examined by western blot analysis. β-Actin was used as a control. The expression levels of iNOS and COX-2 relative to β-actin were quantified by densitometry. Values are expressed as the mean ± standard deviation of 3 replicates for each condition. ^\*\*\*^P\<0.001 vs. vehicle-treated control; ^\#^P\<0.05, ^\#\#^P\<0.01, ^\#\#\#^P\<0.001 vs. LPS only group. iNOS, inducible nitric oxide synthase; COX, cyclooxygenase; SCRT, Socheongryong-Tang; LPS, lipopolysaccharide.](IJMM-41-05-2771-g02){#f3-ijmm-41-05-2771}

![Inhibitory effects of SCRT on LPS-induced production of the pro-inflammatory cytokines (A) TNF-α, (B) IL-1β and (C) IL-6 in RAW 264.7 cells. The cells (5×10^5^/ml) were treated with SCRT (0.25, 0.5 and 1 mg/ml) for 1 h, followed by induction with 1 *μ*g/ml LPS for 20 h. Control cells were incubated with vehicle alone. The levels of the pro-inflammatory cytokines were measured using ELISA. Values are expressed as the mean ± standard deviation of 3 replicates for each condition. ^\*\*^P\<0.01 vs. vehicle-treated control; ^\#\#^P\<0.01 vs. LPS only group. SCRT, Socheongryong-Tang; LPS, lipopolysaccharide; TNF, tumor necrosis factor; IL, interleukin.](IJMM-41-05-2771-g03){#f4-ijmm-41-05-2771}

![Inhibitory effects of SCRT on the LPS-induced activation of (A) p-I-κBα and (B) nuclear NF-κB (p65). RAW 264.7 cells at a concentration of 5×10^5^/ml were treated with SCRT (0.25, 0.5 or 1 mg/ml) for 1 h and then with LPS (1 *μ*g/ml) for 15 min. Control cells were treated with vehicle only. Western blot analysis was performed to determine the protein levels of p-I-κBα and NF-κB (p65). The level of p-I-κBα vs. β-actin and NF-κB (p65) vs. Lamin A/C were quantified by densitometry. Values are expressed as the mean ± standard deviation of 3 replicates for each condition. ^\*\*^P\<0.01 vs. vehicle-treated control; ^\#\#^P\<0.01 vs. LPS only group. SCRT, Socheongryong-Tang; LPS, lipopolysaccharide; NF-κB, nuclear factor κB; p-I-κBα, phosphorylated inhibitor of NF-κB.](IJMM-41-05-2771-g04){#f5-ijmm-41-05-2771}

![Inhibitory effects of SCRT on the phosphorylation of mitogen-activated protein kinases (JNK, ERK and p38) in LPS-stimulated RAW 264.7 cells. The cells were treated with the indicated concentrations of SCRT for 1 h, followed by induction with 1 *μ*g/ml LPS for 15 min. Western blot analysis was performed using anti-phosphokinase antibodies for cell extract analysis. Phosphorylated JNK, ERK1/2 and p38 vs. total JNK, ERK1/2 and p38 were measured via densitometry. Values are expressed as the mean ± standard deviation of 3 replicates for each condition. ^\*\*^P\<0.01, ^\*\*\*^P\<0.001 vs. vehicle-treated control; ^\#\#^P\<0.01, ^\#\#\#^P\<0.001 vs. LPS only group. SCRT, Socheongryong-Tang; LPS, lipopolysaccharide; JNK, c-Jun N-terminal kinase; p-ERK, phosphorylated extracellular signal-regulated kinase.](IJMM-41-05-2771-g05){#f6-ijmm-41-05-2771}

![Effects of SCRT on CA-induced paw edema volume and expression of iNOS and COX-2 by CA in the paw tissues. Rats were orally pretreated with DEXA (1 mg/kg, p.o., 3 days) or SCRT (0.3 or 1 g/kg, p.o., 3 days) and subcutaneously injected with 1% CA (100 *μ*l/rat, dissolved in sterilized saline). (A) The volume of paw swelling was recorded at 0-4 h after CA injection. (B) The protein from paw tissue samples of rats at 4 h after CA injection was isolated and the expression of iNOS and COX-2 was determined using western blot analysis. β-actin was used as a loading control. Values are expressed as the mean ± standard deviation of 3 replicates for each condition. ^\*\*^P\<0.01, ^\*\*\*^P\<0.001 vs. vehicle-treated control; ^\#^P\<0.05, ^\#\#^P\<0.01, ^\#\#\#^P\<0.001 vs. CA only group. SCRT, Socheongryong-Tang; LPS, lipopolysaccharide; DEXA, dexamethasone; CA, carrageenan; iNOS, inducible nitric oxide synthase; COX, cyclooxygenase; p.o., *per os*.](IJMM-41-05-2771-g06){#f7-ijmm-41-05-2771}

![Histological images of the dorsal pedis skin. Tissue sections from the dorsal pedis of the (A) Control, (B) CA, (C) CA and dexamethasone-treated, (D) CA and SCRT (0.3 g/kg)-treated and the (E) CA and SCRT (1.0 g/kg)-treated rats were stained with hematoxylin and eosin or toluidine blue for histo-pathological examination. The arrow indicates the total thickness and scale bars indicate 40 *μ*m. CM, cutaneous muscle; DM, dermis; ED, epidermis; HD, hypodermis; HF, hair follicle; SE, sebaceous gland; SCRT, Socheongryong-Tang; LPS, lipopolysaccharide.](IJMM-41-05-2771-g07){#f8-ijmm-41-05-2771}

![Histological images of the ventral pedis skin. Tissue sections from the ventral pedis of the (A) Control, (B) CA, (C) CA and dexamethasone-treated, (D) CA and SCRT (0.3 g/kg)-treated and the (E) CA and SCRT (1.0 g/kg)-treated rats were stained with hematoxylin and eosin or toluidine blue. The arrow indicates the total thickness and scale bars indicate 40 *μ*m. DM, dermis; ED, epidermis; HD, hypodermis; PM, paw muscle; SCRT, Socheongryong-Tang; LPS, lipopolysaccharide.](IJMM-41-05-2771-g08){#f9-ijmm-41-05-2771}

###### 

Contents of 5 marker compounds in Socheongryong-Tang as determined by ultra performance liquid chromatography (n=3).

  Compound        Content (*μ*g/ml)
  --------------- -------------------
  Ephedrine       21.7±0.41
  Paeoniflorin    10.7±1.09
  Cinnamic acid   0.19±0.02
  Glycyrrhizin    2.50±0.03
  Gomisin-A       1.97±0.08

###### 

Changes in the histomorphometrical parameters of paw skins.

  Group             Dorsal pedis skin                                                                                                Ventral pedis skin                                                                                                                                                                                                                                                                                                                                                                                                                                        
  ----------------- ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------
  Control           937.49±221.08                                                                                                    28.60±11.80                                                                                                   58.20±9.98                                                                                                   595.58±53.73                                                                                                     20.20±5.89                                                                                                    35.00±5.10
  CA                2,367.14±369.77[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"}                                                   288.60±17.64[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"}                                                   19.40±2.30[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"}                                                    1,382.58±165.53[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"}                                                   473.60±45.64[b](#tfn3-ijmm-41-05-2771){ref-type="table-fn"}                                                   12.00±2.35[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"}
  Dexamethasone     1,306.65±98.70[c](#tfn4-ijmm-41-05-2771){ref-type="table-fn"},[d](#tfn5-ijmm-41-05-2771){ref-type="table-fn"}    113.20±24.79[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"},[c](#tfn4-ijmm-41-05-2771){ref-type="table-fn"}   40.00±10.98[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"},[c](#tfn4-ijmm-41-05-2771){ref-type="table-fn"}   912.94±175.95[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"},[c](#tfn4-ijmm-41-05-2771){ref-type="table-fn"}     197.40±17.04[b](#tfn3-ijmm-41-05-2771){ref-type="table-fn"},[e](#tfn6-ijmm-41-05-2771){ref-type="table-fn"}   27.80±4.71[c](#tfn4-ijmm-41-05-2771){ref-type="table-fn"},[d](#tfn5-ijmm-41-05-2771){ref-type="table-fn"}
  SCRT (0.3 g/kg)   1,925.25±217.35[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"},[c](#tfn4-ijmm-41-05-2771){ref-type="table-fn"}   258.80±38.32[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"}                                                   22.40±6.91[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"}                                                    1,309.70±162.60[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"}                                                   412.80±55.88[b](#tfn3-ijmm-41-05-2771){ref-type="table-fn"}                                                   11.00±2.55[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"}
  SCRT (1 g/kg)     1,632.05±86.02[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"},[c](#tfn4-ijmm-41-05-2771){ref-type="table-fn"}    173.40±16.70[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"},[c](#tfn4-ijmm-41-05-2771){ref-type="table-fn"}   40.80±7.69[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"},[c](#tfn4-ijmm-41-05-2771){ref-type="table-fn"}    1,109.76±108.75[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"},[c](#tfn4-ijmm-41-05-2771){ref-type="table-fn"}   334.80±38.34[b](#tfn3-ijmm-41-05-2771){ref-type="table-fn"},[e](#tfn6-ijmm-41-05-2771){ref-type="table-fn"}   20.60±6.31[a](#tfn2-ijmm-41-05-2771){ref-type="table-fn"},[c](#tfn4-ijmm-41-05-2771){ref-type="table-fn"}

Values are expressed as the skin index as a mean ± standard deviation of 5 rat hind paws.

P\<0.01 compared with control group by the LSD test.

P\<0.01 as compared with the control group by the MW test.

P\<0.01 compared with the CA group by the LSD test.

P\<0.05 compared with the control group by the LSD test

P\<0.01 as compared with the CA group by the MW test. SCRT, Socheongryong-Tang; CA, carrageenan; IF, infiltrated inflammatory cells; LSD, least-significant differences; MW, Mann-Whitney U test.

[^1]: Contributed equally
